Secukinumab Shows Benefit for Hidradenitis Suppurativa at 1 Year Secukinumab Shows Benefit for Hidradenitis Suppurativa at 1 Year

Currently, the tumor necrosis factor inhibitor adalimumab is the only biologic therapy approved for the treatment of moderate to severe hidradenitis suppurativa.MDedge News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news